Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SENATR

Financiado

Sensing Aberrant Transcription by MYC Multimers

Deregulated expression of MYC or one of its paralogues, MYCN and MYCL, maintains the growth of most human tumors. All current models explain the oncogenic potential of MYC proteins by their ability to form complexes with MAX that... ver más

30/04/2028

UNI WUERZBURG

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

JULIUSMAXIMILIANSUNIVERSITAT WURZBURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-18

ERC-2022-ADG: ERC ADVANCED GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNI WUERZBURG

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BFU2014-52529-R MECANISMOS DE ESTABILIZACION DE HORQUILLAS DE REPLICACION: R... Cerrado

BFU2008-00238 CONEXIONES ENTRE REMODELACION DE LA CROMATINA, ELONGACION DE... 15K€ Cerrado

MYCinTOPshape Mechanism and targeting of topoisomerase regulatory interact... 2M€ Cerrado

RTI2018-094094-B-I00 ANALISIS DE LA RELACION FUNCIONAL ENTRE MYC Y MAX EN LINFOCI... 163K€ Cerrado

BFU2009-09036 PAPEL DE LA DINAMICA DE LA CROMATINA EN LA INTEGRIDAD GENOMI... 188K€ Cerrado

BFU2013-48374-P STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF TRANSCRIPTION... 260K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2023-04-18
Fecha Fin: 2028-04-30

Líder del proyecto

JULIUSMAXIMILIANSUNIVERSITAT WURZBURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Deregulated expression of MYC or one of its paralogues, MYCN and MYCL, maintains the growth of most human tumors. All current models explain the oncogenic potential of MYC proteins by their ability to form complexes with MAX that universally bind to active promoters and the ability of these complexes to induce a tumor-specific gene expression pattern. While MYC conforms to this model during unperturbed cell growth, we have discovered two paradigmatic situations in which MYC proteins undergo fundamental changes in their biochemical state, association with MAX and localization on chromatin: In response to pharmacological or physical disruption of transcription elongation, MYC moves away from active promoters to form large, spherical multimers that surround stalled replication forks. These multimers contain transcription termination factors and form a zone that shields stalled forks from RNA polymerase. Second, MYCN forms high molecular weight complexes during the S phase of the cell cycle that do not contain MAX and, like MYC multimers, contain termination factors. Their assembly depends on RNA that is normally degraded by the nuclear exosome, arguing that they too form in response to aberrant transcription. The switch between heterodimeric and multimeric states depends on non-proteolytic ubiquitylation of MYC, which alters protein-protein interactions that retain MYC at promoters. Our data show that MYC proteins exist in a hitherto unknown dynamic equilibrium between globally promoter-bound heterodimers and multimers that form locally in response to perturbed transcription. We aim to show that these dynamics enable tumor cells to cope with stress arising from deregulated transcription and are crucial for MYC´s oncogenic function. We expect that inhibiting MYC multimerization will maintain normal growth but block the ability of tumour cells to cope with deregulated transcription and is therefore a valid therapeutic strategy for targeting oncogenic functions of MYC

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores